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Abstract
The control and prevention of infectious diseases through immunization
is one of the greatest achievements of modern medicine since Edward Jenner
pioneered smallpox vaccination.
However, future challenges in improving the efficacy of existing vacci-
nes, development of new prophylactic vaccines for infectious diseases and
therapeutic immunization for noninfectious diseases require extensive work
to reveal key components of the molecular immune mechanism involved.
Successful activation of innate immune response is a prerequisite for suc-
cessful immunization and activation of adaptive immunity. Innate immu-
ne system comprises numerous evolutionary conserved pattern-recognition
receptors (PRRs) that bind structural components shared by many patho-
gens. Upon binding the ligand, cascade reaction results in de novo gene
expression required for immediate immune response by innate immunity
and the activation of specific immune response mediated by the humoral
and cellular mediators. Appropriate selection of specific pattern-recogni-
tion receptor ligands (adjuvants) enables formulation of the next generation
vaccines, with controlled minimal adverse symptoms and efficient adaptive
immunity development.
DISCOVERY OF PATHOGEN RECOGNITION
RECEPTORS
In 1980’s, obstacles to experimentally induce a development of adap-tive immune response inspired Charles A. Janaway Jr. to propose the
hypothesis that innate immune cells (dendritic cells and macrophages)
recognize pathogen structural molecules (adjuvants) and provide neces-
sary help to T and B cells mounting cellular and humoral immunity
(1). Recognition of these molecules depends on the presence of consti-
tutively expressed receptors, later called pattern-recognition receptors
(PRRs).
First PRR gene, called Toll, was discovered in 1985 by German a
biologist Christiane Nüsslein-Volhard who revealed its prominent role
in the embryogenesis of the fruit fly (2). Ten years later, similarity in
intracellular interleukin (IL)-1 cytokine and Drosophila Toll receptor
signaling coupled with NF-kB-dependent gene transcription led Jules
A. Hoffmann to directly relate Toll with immune responses to fungal
infection in Drosophilla (3)
Only a year later Ruslan Medzhitov and Charles A. Janeway, Jr. at
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receptor (now called TLR4). TLR4 induced NF-kB ac-
tivation in a similar way as ligation of the IL-1 receptor
and Drosophila Toll receptor (4).
At about the same time, Bruce A. Beutler discovered
that mouse TLR4 is the long-sought receptor for lipo-
polysaccharide (LPS), the active component from endo-
toxin in Gram-negative bacteria (5). It became obvious
that TLRs constitute a family of pattern recognition
receptors which bind pathogen-associated molecular pat-
terns and activate immune system as predicted by Charles
A. Janeway, Jr. several years earlier.
Discovery of Toll-like receptors and their role con-
cerning activation of innate immunity by Jules A. Hoff-
man and Bruce A. Beutler was honored by the Nobel
Prize in Physiology or Medicine in 2011. Many contro-
versial discussions have been raised since a letter signed
by 23 prominent immunologists was published in the
Nature, implying that »the seminal contribution of im-
munologists Charles A. Janeway Jr. and Ruslan Medzhi-
tov« should be acknowledged (6).
DIVERSITY OF PATHOGEN
RECOGNITION RECEPTORS
Innate immune mechanisms, due to this widespread
distribution and no additional requirements to effecti-
vely recognize microbial structural moieties (7), repre-
sent a first line of immune defense against microorga-
nisms. The basic mechanisms of pathogen recognition
are evolutionarily conserved and include sensors present
in the plasma, on cellular membranes, and cytosol
(Figure 1), reassembling diversity of different pathogen
biology and life cycle.
The array of PRRs contains several families of host
germline-encoded receptors with the common denomi-
nator of broad specificity to different molecules produced
by invading microbes. These structural molecules, referred
to as pathogen-associated molecular motifs (PAMPs),
have an essential function in the life of a microbe and
include LPS as the major component of the outer layer of
Gram-negative bacteria, peptidoglycan (PGN) as the
major component of the cell wall of Gram-positive bac-
teria, flagellin and bacterial or viral nucleic acids.
PRRs that are able to recognize different PAMPs are
classified in five major families: scavenger receptors (ScR),
C-type lectin receptors (CLR), Toll-like receptors (TLR),
NOD-like receptors (NLR), RIG-I-like receptors (RLR)
and cytosolic DNA sensors (CDS) (Figure 2).
The first discovered PRR in 1979 was the scavenger
receptor (ScR), identified as a transmembrane receptor
capable of binding LPS, acetylated LDL, and certain
polynucleotides contributing to endocytosis-mediated
clearance (8). Besides this group, CLR family members
also recognize a number of pathogen-associated glycan
molecular motifs (9) and, like ScR, they are primarily
involved in endocytosis.
In contrast to ScR and CLR, the families of TLR,
NLR, RLR and CDS receptors, upon ligation of struc-
tural molecular motifs of potentially harmful pathogenic
microorganisms, initiate activation of innate immune
mechanisms that would combat the invader and provide
a platform for adaptive immune response development.
These receptors possess structural domains that bind a
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Figure 2. Pathogen recognition receptors.
PRRs are membrane or soluble molecules that have ability to recog-
nize different pathogem molecules. They have different domains rele-
vant to recognize distinct pathogen-derived molecular motifs and
signaling domains necessary for activation of NF-kB, MAPK and IRF
pathways. CRD, carbohydrate recognition domain; ITIM/ITAM, im-
munoreceptor tyrosine-based inhibitory/activation motif domain;
LRR, leucine rich repeats domain; TIR, Toll/Interleukin-1 receptor
domain; NACHT (NOD), nucleotide-binding oligomerization do-
main; PYD, pyrin domain; BIR, Baculovirus inhibitor of apoptosis
protein repeat domain; CARD, Caspase activation and recruitment
domain; Helicase, helicase domain; RD/CTD, N-terminal receiver
/C-terminal effector domain; HIN200, DNA binding domain.
Figure 1. Pathogen recognition sensors.
Different host molecules recognize and bind pathogen-derived mole-
cules, neutralize and generate signals that would activate potent in-
nate immune mechanism. TLR, Toll-like recptors; CDS, cytosolic
DNA sensors; NLR, Nod-like receptors; RLR, RIG-I-like receptors;
PGRP, peptidoglycan recognition proteins; ScR, scavenger receptors;
CLR, C-type lectin receptors
pathogenic molecule and the signaling domain required
to initiate intracellular cascade in the induction of anti-
microbial genes and inflammatory cytokines (10).
NLRs, RLRs and CDSs are multidomain molecules
localized in the cytosol and therefore sense intracellular
pathogens. NLRs are a family of heterogenic receptors
that are involved in the NF-kB and MAPK activation or
assembly of inflammasome, a multiprotein oligomer re-
quired for the caspase-1-mediated processing of pro-
IL-1b and pro-IL-18 (11, 12).
Since ’whole’ pathogens are composed of different
structural molecules, it is not surprising that multiple
PRRs could be triggered simultaneously by a single mi-
croorganism. The activation of multiple PRRs results in
a combinatorial code that specifically shapes the host
response to a particular class of microbes (13).
Besides foreign pathogen molecular motifs, there is
mounting evidence that certain PRRs are involved in
sensing endogenous non-microbial endogenous 'danger'
signals (14). These endogenous adjuvants could amplify
the innate immune response or possibly contribute to the
development of overwhelmed inflammation due to un-
controlled innate immune response leading to life threa-
tening conditions. In addition, deregulated activation of
intracellular TLRs has been associated with the patho-
genesis of some autoimmune diseases like systemic lu-
pus erythematosus (SLE), confirming a role of PRRs in
adaptive immunity (15).
TOLL-LIKE RECEPTORS
Innate immune defense mechanisms represent a bor-
der line where the host senses microbial presence and
starts the appropriate response. Sharing the same space,
the host has been evolutionally educated to recognize a
symbiotic from a virulent pathogen via conserved patho-
gen recognition receptors shared by different cells and
tissues. In a case of infection with a virulent pathogen
and the presence of tissue destruction, immune defense
mechanisms become activated, beyond activation thres-
hold, by a variety of exogenous pathogen-derived, as well
endogenous, molecules. As important role in this process
is played by TLRs, the best-characterized PRRs which
solely or in combination with other PRRs are capable to
recognize common pathogen/host molecular patterns.
TLRs are members of the interleukin-1-receptor super-
family (Figure 3) and comprise a leucine-rich repeat
(LLR) domain group of transmembrane PRRs that re-
cognize highly conserved microbial molecules (4, 16,
10). Since the discovery of the first Toll-like receptor 4,
TLRs have expanded to a family of structurally cohesive
receptors found to be widespread in vertebrates, arthro-
pods, and nematodes (17, 18, 19). Overall, 13 members of
the TLR family have been described with 10 being func-
tional in humans and 12 in mice (20). TLRs are type 1
transmembrane proteins characterized with amino-ter-
minal extracellular LRR-domain necessary for the recog-
nition of PAMPs. LRR-domains contain a variable num-
ber of hydrophobic leucine rich modules 20-30 amino
acids in length. The extracellular portion of TLRs, due to
LRRs, has a horseshoe shape as a common structural
finding of all family members (21). Recognition of dif-
ferent ligands is primarily determined by the amino acid
sequence, but post-translation modification, micro-en-
vironmental factors like proteolysis-mediated activation
and variable adaptor molecule availability contribute to
the diversity in ligand recognition.
The controlled microbial recognition requires inter-
play of TLRs with different accessory molecules (22). A
number of different accessory molecules cooperate in the
full activation of TLRs. The binding of LPS by TLR4
additionally requires lymphocyte antigen 96 (MD-2),
serum LPS-binding protein (LBP) and CD14 that ac-
celerate intracellular signalosome formation and down-
stream signaling (23).
The members of the TLR family have acquired the
ability to recognize different PAMPs that was evolutio-
nary driven from ancestral TLR gene via a molecular
Period biol, Vol 114, No 2, 2012. 213
Targeting Toll-Like Receptors K. Bendelja and Sabina Rabati}
Figure 3. TIR superfamily.
The TIR superfamily is defined by a common intra-
cellular TIR domain, involved in the initiation of sig-
naling. Toll/IL-1R (TIR) superfamily members enco-
mpasses the Ig domain family (IL-1 receptors, IL-18
receptors, and IL-1R-like receptors), the leucine-rich
domain family (the Toll-like receptors and similar re-
ceptors), and TIR domain family as a series of TIR
domain-containing intracellular adapter molecules, dif-
ferentially recruited to the Toll/IL-1 receptors and con-
tribute to the specificity of signaling.
mechanism involving gene duplication (24) and direc-
tional allotype selection, possibly in response to patho-
gen challenge. This extensive genetic selection has re-
sulted in recognition of the chemically similar microbial
molecules of different origin: lipoproteins and peptido-
glycans by TLR1/2 and TLR2/6; LPS and glycoproteins
by TLR4; proteins like bacterial flagellin by TLR5; double-
-stranded RNA by TLR3 or single-stranded RNA by
TLR7 (in humans also TLR8); CpG DNA by TLR9
(Table 1). The crystallographic analysis of TLR-ligand
interaction employing 'hybrid LRR method' has demon-
strated that hydrophobic ligands specific for TLR1, TLR2,
and TLR4 bind within internal protein pockets while
hydrophilic ligands, like double-stranded RNA, interact
with TLR3 via the surface of LRR-domain. Binding of
specific ligands, in a homotypic or heterotypic TLR-
-dimer format, induces dimerization of the ectodomains
forming dimers strikingly similar in shape. These
'm'-shaped complexes, the C-termini of the extracellular
domains of the TLRs, converge in the middle. This
observation suggests the hypothesis that, upon dimeriza-
tion, the extracellular domains undergo conformational
changes and force allosteric activation and dimerization
of the intracellular signaling TIR domains (21).
It is not surprising that TLRs expressed on the cell
surface (TLRs 1, 2, 4, 5, 6, 10) primarily recognize bacte-
rial structural components, while those expressed within
cellular compartments, like ER, endosomes, and lyso-
somes (TLRs 3, 7, 8, 9), are critical for the recognition of
viral products and nucleic acids (25, 26, 27). Functional
activity of these intracellular TLRs requires lower pH for
efficient ligand binding and downstream signaling that
could be blocked by endosomal acidification inhibitor
choroquine (28). Although it was originally considered
that single-stranded RNA ligand binding to TLR7 and
TLR8 does not require specific nucleotide sequence,
Heil et al. (27) have shown that GU-rich ssRNA repre-
sents physiological ligand for those TLRs as previously
shown for TLR9 that recognizes unmethylated linear
CpG oligonucleotide sequences (29).
TLR SIGNALING
TLRs represent the key components of both innate
and adaptive immunity and allow distinction between
self and nonself via specific recognition mechanisms.
Despite diverse mechanisms of ligand interaction, the
organization of ligand-TLR dimer complexes may apply
to all TLRs. The formation of 'm' shaped TLR dimer
structure causes dimerization of the intracellular do-
mains for signal initiation (21). The resulting TIR-TIR
complex initiates downstream signaling through recruit-
ment of specific adaptor molecules (Figure 4). So far, five
adaptors with TIR domain have been described: myeloid
differentiation factor 88 (MyD88), MyD88-adaptor like
(MAL), TIR domain-containing adaptor inducing IFN-
-beta (TRIF), TRIF-related adaptor molecule (TRAM),
and sterile alpha and heat-Armadillo motifs (SARM)
(30). Depending on the adaptors recruited, downstream
signaling events could be, in general, split in two path-
ways: (1) MyD88-mediated pathway resulting in activation
of transcription factor NFkB (all TLRs except TLR3), or
TRIFF-mediated pathway (MyD88-independent path-
way) leading to activation of the interferon-regulated
factors (IRF), family of transcription factors (31, 22).
MyD88 also contains another protein interaction do-
main, the death domain (DD) that enables subsequent
association with the DD-bearing IL-1 receptor-associated
kinases (IRAK) through homophilic DD-DD interac-
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Figure 4. TLR signaling..
The toll-like receptors act in response
to spectra of molecular patterns from
different bacteria and viruses. TLR-
-specific signaling pathway leads to the
recruitment of different adaptors and
signaling molecules leading in down-
stream activation of NF-kB, MAPK
and IRF pathways. Those pathways
are responsible for innate inflamma-
tory (cytokines and chemokines) and
acquired immunity response (co-sti-
mulatory molecule expression).
tion, to receptor-adapter complex. MyD88 pathway, be-
sides IRAK-1 and IRAK-4 serin/threonin kinases, involves
TNF receptor-associated factor 6 (TRAF-6) and other
mitogen-activated kinases (MAPK) that associate with
Pellino scaffold protein assembling the signalosome ne-
cessary for NFkB activation (32). The Pellino protein
enables tethering multiple members of a TLR-signaling
pathway that culminate in the NFkB-mediated trans-
cription of pro-inflammatory cytokine genes such as IL-1,
IL-6, TNF-a, IL-12, IFNs, chemokines, adhesion mole-
cules, co-stimulatory molecules, growth factors, tissue-
-degrading enzymes such as metalloproteinases, and en-
zymes that generate inflammatory mediators such as
cyclo-oxygenase 2 and inducible nitric oxide synthetase
(33). In contrast, TRIF pathway predominantly results
in IRF-mediated synthesis of interferons and potent anti-
viral immune response.
Different microbial agents could trigger multiple path-
ways in different cell types and induce the expression of a
distinct subset of genes ultimately shaping innate and
adaptive immune responses (34, 35). Interestingly, acti-
vation of TLR4 by LPS can consolidate both TRIF and
MyD88-dependent pathways, inducing pro-inflamma-
tory and anti-viral execution program.
BRIDGING INNATE AND ADAPTIVE
IMMUNITY BY TLR AGONISTS
The sensing of the environment by TLRs and sub-
sequent cellular response to infection via signaling path-
ways are some of the earliest events of immune response.
The most diverse repertoire of TLRs has been detected in
hempoietic immune cells (36). In addition to the im-
mune cells, non-immune cells can also respond to TLR
stimulation. Most of them express some TLRs, including
epithelial and endothelial (37) cells of the genital tract
(38), intestinal tract (39), and respiratory tract (40). As
frontline of infection, these cells recognize pathogens
and release cytokines and chemokines that could in turn
modulate TLR expression (41). They also release cyto-
kines and chemokines to initiate inflammatory response
as result of the immune cell recruitment. Among them,
dendritic cells (DC), first described by Steinmen RM
(Nobel Prize laureate for 2011.), have a central role in the
development of adaptive response (42).
DCs are professional antigen (Ag)-presenting cells,
comprising a complex subsets of cells with distinct mye-
loid (myeloid DC) or lymphoid (plasmacytoid DC) ori-
gin (43). The immature DCs have a potent inherited
capacity to internalize and process antigens, but when
stimulated they mature, express high levels of surface
co-stimulatory molecules and release cytokines to
optimally regulate primary/secondary T cell responses.
DCs constantly patrol in different tissues, uptake
pathogens and present Ag to T cells. Critical function of
DCs is to sense an invading pathogen by mechanisms of
innate immunity and transfer the information about the
threat to adaptive immune system. One of the key
mechanisms is PRR-PAMP interaction that could sensi-
bilize DCs about possible danger. DCs are armed with a
collection of pattern recognition receptors that can speci-
fically interact with pathogen PAMPs, including the
mannose receptors, c-type lectins, TLRs and others (44,
45). Among these, TLRs have drawn lot of attention in
recent years due their diversity and strong activation
potential. In humans, 11 different TLRs have been iden-
tified, each reacting with different pathogen patterns
(Table 1).
Different subsets of DCs could express different
TLRs. For example, human myeloid DCs (mDC) have
been shown to express all TLRs except TLR7 and TLR9
whereas plasmacytoid DCs (pDC) have more limited
pattern with predominant TLR7 and TLR9 expression
(46, 47). It has been proposed that DCs use many diffe-
rent TLRs to detect several features of a pathogen si-
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TABLE 1
Diversity of TLR ligands.
hTLR Cell. location PAMP Cytokine profile Immune response

















TLR5 surface membrane flagellin IL12p70high Thl
TLR7 endosome membrane viral ssRNA IFN-ahigh Thl
TLR8 endosome membrane Virak ssRNA IL12p70high
IFN-a
Thl
TLR9 endosome membrane unmethylated DNA IFN-ahigh Thl
TLR10 surface membrane ? ? ?
multaneously and transmit ’danger signal’ to direct a
specific response. Thus, TLR-induced signals could serve
as one of the mechanisms of self/non-self discrimination
(48). Triggering distinct TLRs on DCs also elicits dif-
ferent cytokine profiles, resulting in specific activation
status and capability of DCs to shape adaptive immune
response. For example, signals triggered via TLR7 and
TLR9 in pDCs can activate downstream IRF7 pathway
and predominant interferon (IFN)- production (47).
The discovery that pDCs are the major source of
IFN- during virus infections established that lymphoid
DCs as a key player in the defense against intracellular
pathogens. Upon encounter with naïve T cells, pDC
force Th1 differentiation via IFN-a-dependent mecha-
nism. In contrast, signals generated by triggering TLRs
in the mDCs lead to the production of large quantities of
IL-12p70, a cytokine that also favors the differentiation
of Th1 cells and IFN- production (49).
MyD88-TRAF6 interaction in DCs is followed by the
activation of NF-kB, JNK, p38 MAPK and expression
of different genes responsible for the generation of Th1,
Th2, or other helper T cell subsets and cytotoxic T cells.
DCs efficiently upregulate CCR7 and migrate to T cell
area in the lymph nodes (46) as well co-stimulatory
molecules CD40, CD80 and CD86, providing the se-
cond activation signal to T cells necessary for their dif-
ferentiation and proliferation (49).
Once activated by PAMPs, DCs acquire full capability
to react but additional studies have demonstrated that
micro-environmental factors could influence the deve-
lopment of immunity or tolerance (50). Immature DCs
express a low level of co-stimulatory molecules and cyto-
kines, and it was postulated that immaturity tends to
induce anergy or tolerance of T cells, whereas matura-
tion of DCs is required to optimally activate T cells (51).
However, reports suggest that DCs are also required
to display a mature phenotype to successfully mediate
tolerance induction (52). Therefore it is more accurate to
define the role of a subset of DCs by the effects they
confer on the immune system (53).
Since TLR ligands appear to promote the capacity of
DCs in the induction of T cell responses, reasonably
many have focused on the application of TLR ligands as
a component of the next vaccine generations against
infectious diseases and cancer. But before TLR ligands
are about to be used as adjunctive agent in human vac-
cines, better understanding of the effect of TLR agonist
on the activation of DCs and the regulation of immune
responses by different DCs must be achieved.
USE OF TLR-AGONISTS IN
PROPHYLACTIC AND THERAPEUTIC
VACCINES
The era of immunization started when the first vaccine
against rabies was made by Louis Pasteur and Pierre Paul
Émile Roux in 1885. Later, at the beginning of the 20th
century, many bacterial and viral vaccines entered im-
munization protocols that consisted of whole pathogens
able to trigger many PRR-ligands even before relevant
innate recognition receptors have been discovered.
Although mechanisms of action were not characteriz-
ed at the time, it was observed that the addition of bacte-
rial extracts exhibited adjuvant potency and would in-
crease antibody production to the given antigen. A
number of preparations were developed, like Freund
adjuvant and Coley adjuvant. These formulations were
enriched with different bacterial products but, due to
exaggerated adverse effects, were used only experi-
mentally. Adjuvant characteristic to stimulate the im-
mune system without specific antigenic effect was used
to increase the response to a vaccine, and generally adju-
vants represent the essential part of an effective vaccine.
Biological characteristics of potent adjuvants could be
described as rendering them capable to: (1) accelerate the
generation of robust, long lasting immune responses; (2)
generate antibodies with increased avidity and neutrali-
zation capacity; (3) enhance immune responses in
individuals with weakened immune systems; (4) reduce
the amount of antigen and number of doses needed
while reducing the cost of vaccination programs; (5)
activate the cellular arm of adaptive response.
TLR-AGONISTS IN INFECTIOUS
DISEASES
A large number of microbial components exhibit po-
tent adjuvant properties and represent novel tools in
creating vaccines. The older generations of vaccines for
infectious diseases used attenuated or inactivated whole-
-pathogen formulations, incorporating all or most of
pathogen derived antigens. These systems included a
number of different antigens capable to stimulate innate
and adaptive immunity, and sufficient to establish the
productive immune response. But balance between im-
munogenicity and occurrence of adverse effects was jeo-
pardized by overwhelming inflammatory reaction dri-
ven by activation of many PRR-mediated mechanisms.
Clear example is pertussis vaccine where use of cellular
pertussis vaccine has led to development of the protective
immunity in vaccinated children and a decrease in di-
sease prevalence during the last century. But in a number
of vaccinated children, adverse effects were identified
like serious irreversible brain damage that concomitantly
influenced the development of acellular pertussis vac-
cine (54). The acellular vaccine contains purified and
detoxified pertussis toxin as a major bacterial antigen
responsible for disease protrusion plus filamentous he-
magglutinin and pertactin adsorbed on aluminum salts.
Exclusion of a whole bacterial cell from vaccine formu-
lation resulted in a removal of many different molecules
with PRR-agonistic activity that could be responsible for
the observed adverse post-vaccinated symptoms. Acel-
lular formulation contains aluminum salts whose adju-
vant activity seems to be related to inflammasome acti-
vation although there are conflicting findings (55).
Aluminum salts (Alum) have been in use for more than
80 years in vaccine formulations and showed strong sa-
216 Period biol, Vol 114, No 2, 2012.
K. Bendelja and Sabina Rabati} Targeting Toll-Like Receptors
fety profile and effectiveness, even before the mechanism
of action has been determined. In this case, selection of
an appropriate adjuvant with exact dose contributed in
protective immune response and decrease of adverse
symptoms in vaccinated children.
Another good example is whole virus vaccine against
influenza virus that was introduced in 1940 in inactivat-
ed form. Although highly immunogenic, this vaccine
form was accompanied with more frequent adverse ef-
fects than inactivated split or subunit vaccine (56). De-
spite that, inactivated whole virus influenza vaccine still
comprises about 30% of all influenza vaccine produc-
tion; the rationale for the development of split influenza
virus vaccine could be the ability of viral surface proteins
to solely activate TLR4 (57) and initiate immune respon-
se. On the other hand, whole virus vaccine has additional
pathogen associated molecules that could trigger other
PRRs. Related to intracellular viral life cycle, host cells
have developed intracellular receptors that sense viral
nucleic acid during replication phase. Intracellular PRRs
that recognize influenza virus are TLR3, TLR7, TLR8
(in humans) and later discovered RIG-I and MDA-5
receptors (58). Depending on a manufacturing protocol,
innate recognition of split and inactivated influenza vi-
rus relies probably on TLR4, TLR3, TLR7 and TLR8
but not RIG-I pathway since it could be exclusively
triggered only by the live virus. As in a case of acellular
pertussis vaccine, immunogenicity of split influenza vac-
cine is reduced and therefore different adjuvants are
included. One of them is squalene (MF59) that exhibits
potent adjuvant MyD88-dependent activity, independent
of TLRs and inflammasome (55).
Discovery of PRRs and their specific ligands as potent
adjuvants accelerated the research of natural and synthetiz-
ed compounds for possible clinical application. Currently
only monophosphoryl lipid A (MPL) FDA licensed adju-
vant (TLR4 ligand) is used in Cervarix®, a prophylactic
vaccine against HPV types 16 and 18, and Fendrix® a hepa-
titis B vaccine both manufactured by GlaxoSmithKline.
MPL is a nontoxic derivate of LPS discovered in 1979 by
Ribi et al. (59), specifically recognized by the TLR4 but,
unlike LPS, it triggers complete TRIF and incomplete
MyD88 signaling without activation of caspase-1 re-
quired in the processing of biologically active IL-1
directly related to reduced toxicity (60).
Immunostimulatory activity of imiquimod (TLR7 ago-
nist) which has not yet been used as an adjuvant in
vaccine preparations, is the first TLR-based medication
FDA-approved in 1997 to treat actinic keratosis, super-
ficial basal cell carcinoma, and external genital warts. As
immune response modifier, imiquimod acts on innate
and specific immunity to eradicate premaligant and hu-
man papillomavirus infected epithelial cells.
TLR-AGONISTS IN CANCER
Discovery that TLR7 agonist imiquimod can act upon
immune system eradicate to malignant disease has re-
newed interest in the concept of immunotherapy as an
approach to cancer treatment. The role of adjuvants in
anti-cancer treatment had been studied in different
systems employing mycobacterial and bacterial structural
elements before information about PPRs has emerged.
Detailed insight in the mechanisms involved and
discovery of a spectrum of different PRRs that can be
triggered by microbial products led to numerous precli-
nical and clinical studies to evaluate single or multiple
agonists that can elicit effective anti-tumor adaptive im-
mune response and possibly eradicate disease. The most
studied are agonists recognized by intracellular TLRs
that once triggered by a specific ligand, stimulate type I
IFN production known to have a beneficial role in anti-
-cancer immune response. Moreover, stimulation of in-
tracellular TLRs in Treg cells can overcome their regula-
tory function, allowing the reactivation of anergic tumor
specific effector T cells and lysis of tumor cells (61). It is
not surprising that adjuvants play an essential and central
role in the next generation of cancer vaccines (62). An
example is anti-cancer vaccine that besides antigen,
utilizes three different adjuvants (squalene, MPL and
CpG), two of them being TLR4 and TLR9 agonists with
potent immunomodulatory activity.
STRATEGIES FOR NEXT GENERATION
ADJUVANTS
Targeting intracellular TLRs
Several companies are developing promising new adju-
vant candidates based on triggering intracellular TLRs as
a potent immunostimulatory platform for infectious
diseases and cancer.
3M Drug Delivery Systems has a portfolio of patent-
-protected TLR agonists that have shown promise as
vaccine adjuvants. The lead candidate, resiquimod (TLR7/8
agonist) has shown promising results in a number of
animal models and has an extensive toxicology and cli-
nical data package to support further development as a
cancer vaccine adjuvant (63).
Celldex Therapeutics, Inc. entered a non-exclusive cli-
nical research collaboration with 3M Drug Delivery Sys-
tems to access resiquimod for clinical study with the
company’s Antigen Presenting Cell (APC) Targeting Tech-
nology™ based on CDX-1401, a fusion protein consisting
of a fully human monoclonal antibody with specificity
for the dendritic cell receptor DEC-205 linked to the
NY-ESO-1 tumor antigen, which is currently in a Phase
I/II trial in combination with immune stimulating
agents from 3M Drug Delivery Systems for advanced
cancers of the bladder, breast, ovary, non-small cell lung
cancer, myeloma, sarcoma and melanoma.
Juvaris BioTherapeutics, Inc. entered into an exclusive
license agreement with Colby Pharmaceutical Company
for the worldwide development and commercialization of
Juvaris’ Cationic Lipid-DNA Complex technology and
related JVRS-100 product candidate. JVRS-100 contains
un-methylated DNA that serves as a potent TLR9 ligand.
When combined with a split influenza vaccine antigen,
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JVRS-100 stimulates the adaptive immune response in-
cluding specific antibodies and T-cell responses (64).
Idera Pharmaceuticals have developed numerous com-
pounds that act as agonists for TLR3, TLR7, TLR8, or
TLR9, which the company believes have the potential to
be used as adjuvants in vaccines. In preclinical animal
models, Idera’s TLR agonists have shown adjuvant acti-
vity when combined with various types of antigens (65).
VentiRx Pharmaceuticals, Inc. has several TLR8 ago-
nist candidates that have entered clinical trials in allergic
and cancer diseases, as single or adjunctive agents.
GlaxoSmithKline, Inc. have launched a clinical trial with
GSK2245035 compound that is a highly selective TLR7
agonist. Intranasal administration of GSK2245035 causes
changes in the upper airway microenviroment driven by
IFN- that could alter a bystander’s immune responsi-
veness to aeroallergens and contribute to reduction of al-
lergic reactivity in subjects with respiratory allergies (66).
Targeting surface TLRs
Encouraged by the MPL clinical achievements, many
clinical trials related to TLR4 ligands have been intro-
duced. Moreover, other surface TLRs have been explored
for their specificity and potency as possible vaccine ad-
juvants.
Allergy Therapeutics, Inc. have conducted clinical phase
II evaluation of gradually increasing quantities of an
allergen with MPL in patients allergic to birch, hazel,
alder rye and grass pollen. Allergen-specific immuno-
therapy combined with MPL, a TLR4 agonist, repre-
sents a curative approach which directly treats the un-
derlying allergic disease by possibly changing specific
immune response profile (67).
Immune Design Corp. is developing its proprietary
adjuvant known as glucopyranosyl lipid A (GLA) based
on successful implementation of the first TLR4-specific
agonist MPL in several vaccine formulations. GLA is a
novel generation of human TLR4 agonists. GLA is a
pure synthetic small molecule, manufacture with excellent
stability and rationally designed to optimally activate
human TLR4 receptors, that elicits broad humoral and
cellular immunity (68). GLA was also shown to be safe
and well-tolerated in human in Phase I clinical study in
combination with the influenza virus vaccine Fluzone®
manufactured by Sanofi Pasteur.
CONCLUSIONS
Natural TLR ligands represent pathogen derived mo-
lecules that immune systems recognize as potential threat
and act upon in order to sustain microbial spread and
harm they might cause. Details about the exact mecha-
nisms of action and key pathways involved enable the
design of preferable immune responses by formulated
next generation vaccines with selected TLR-ligands, in-
dividually or in combination with other PRR-ligands.
Proper formulation and exact molecular composition
lead to the development of TLR-ligands capable of in-
ducing robust directed CD4 or CD8 T cell responses, as
well as affecting the quality and quantity of humoral
responses. Employment of proprietary TLR ligands would
enable the fine tuning of adaptive immune responses in
specific target groups, like infants and the elderly.
At the same time, advanced vaccine formulations would
exclude over-activation of inflammation with the establish-
ment of active balance between immune-reactivity and
immune-regulatory mechanisms. This is extremely im-
portant in the case of intracellular TLR ligand formula-
tions since the development of some autoimmune disea-
ses has been related to deregulated TLR7 and TLR9
activation.
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